The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 3, 2011, Pages 197-211

  Chionh, Fiona ^a   Mitchell, Gillian ^b   Lindeman, Geoffrey J ^a   Friedlander, Michael ^c   Scott, Clare L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

BRCA1; BRCA2; Breast cancer; DNA repair; Ovarian cancer; PARP

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INIPARIB; IRINOTECAN; MK 4827; NAVELBINE; OLAPARIB; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER RISK; CELL DEATH; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXCISION REPAIR; FATIGUE; GENE MUTATION; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VOMITING;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 80052243196     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01430.x     Document Type: Review

References (76)

1. Bryant HE, Schultz N, Thomas HD etal. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-17.
2. Farmer H, McCabe N, Lord CJ etal. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
3. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39: 8-24.
4. Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 2010; 53: 4561-84.
5. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-28.
6. Papeo G, Forte B, Orsini P etal. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 2009; 19: 1377-400.
7. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007; 7: 515-23.
8. Ame JC, Rolli V, Schreiber V etal. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999; 274: 17860-8.
9. Yelamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008; 14: 169-78.
10. Menissier de Murcia J, Ricoul M, Tartier L etal. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003; 22: 2255-63.
11. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 1996; 93: 1753-8.
12. de Murcia JM, Niedergang C, Trucco C etal. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 1997; 94: 7303-7.
13. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998; 78: 1269-77.
14. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
15. Ashworth A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-90.
16. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011; 108: 3406-11.
17. Menear KA, Adcock C, Boulter R etal. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581-91.
18. Donawho CK, Luo Y, Penning TD etal. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-37.
19. O'Shaughnessy J, Osborne C, Pippen JE etal. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
20. O'Shaughnessy J, Schwartzberg LS, Danso MA etal. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastaic triple-negative breast cancer (TNBC). In: 2011 ASCO Annual Meeting: J Clin Oncol 29: 2011 (suppl; abstr 1007).
21. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-47.
22. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-72.
23. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-5.
24. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 1310-16.
25. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004; 4: 814-19.
26. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
27. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res 2006; 12: 4463-8.
28. Stark JM, Pierce AJ, Oh J, Pastink A, Jasin M. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol 2004; 24: 9305-16.
29. Tutt A, Bertwistle D, Valentine J etal. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20: 4704-16.
30. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-72.
31. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511-18.
32. Zhuang J, Zhang J, Willers H etal. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res 2006; 66: 1401-8.
33. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009; 18: 31-43.
34. Haber JE. DNA recombination: the replication connection. Trends Biochem Sci 1999; 24: 271-5.
35. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005; 25: 7158-69.
36. Gottipati P, Vischioni B, Schultz N etal. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010; 70: 5389-98.
37. Fong PC, Yap TA, Boss DS etal. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-19.
38. Fong PC, Boss DS, Yap TA etal. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
39. Tutt A, Robson M, Garber JE etal. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
40. Audeh MW, Carmichael J, Penson RT etal. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-51.
41. Kaye S, Kaufman B, Lubinski L etal. Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA 1 and/or BRCA2 mutations. In: 2010 35th ESMO Congress: Annals of Oncology; 21 (Supplement 8): viii304-viii313, Abstract 9710.
42. Merajver SD, Pham TM, Caduff RF etal. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995; 9: 439-43.
43. McCabe N, Turner NC, Lord CJ etal. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
44. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
45. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21: 1761-5.
46. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999; 18: 1957-65.
47. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94: 61-7.
48. Baldwin RL, Nemeth E, Tran H etal. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60: 5329-33.
49. Esteller M, Silva JM, Dominguez G etal. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
50. Collins N, Wooster R, Stratton MR. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 1997; 76: 1150-6.
51. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007; 8: 735-48.
52. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004; 23: 1000-4.
53. Narayan G, Arias-Pulido H, Nandula SV etal. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 2004; 64: 2994-7.
54. Taniguchi T, Tischkowitz M, Ameziane N etal. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568-74.
55. Hughes-Davies L, Huntsman D, Ruas M etal. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003; 115: 523-35.
56. Bryant HE, Helleday T. Inhibition of poly(ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006; 34: 1685-91.
57. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-6.
58. Vorechovsky I, Luo L, Ortmann E, Steinmann D, Dork T. Missense mutations at ATM gene and cancer risk. Lancet 1999; 353: 1276.
59. Bullrich F, Rasio D, Kitada S etal. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999; 59: 24-7.
60. Bell DW, Varley JM, Szydlo TE etal. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-31.
61. Miller CW, Ikezoe T, Krug U etal. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 2002; 33: 17-21.
62. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52: 25-33.
63. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010; 46: 9-20.
64. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-18.
65. Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008; 13: 395-400.
66. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235-44.
67. Nielsen TO, Hsu FD, Jensen K etal. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
68. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-81.
69. Foulkes WD, Stefansson IM, Chappuis PO etal. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-5.
70. Sorlie T, Tibshirani R, Parker J etal. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-23.
71. Dent RA, Lindeman GJ, Clemons M etal. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. In: 2010 ASCO Annual Meeting: J Clin Oncol 28:15s, 2010 (suppl; abstr 1018).
72. Gelmon KA, Hirte HW, Robidoux A etal. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. In: 2010 ASCO Annual Meeting: J Clin Oncol 28:15s, 2010 (suppl; abstr 3002).
73. Tan DS, Rothermundt C, Thomas K etal. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-6.
74. Ledermann JA, Harter P, Gourley C etal. Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). In: 2011 ASCO Annual Meeting: J Clin Oncol 29: 2011 (suppl; abstr 5003).
75. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009; 12: 153-6.
76. Balmana J, Domchek SM, Tutt A, Garber JE. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discovery 2011;1. Epub ahead of print, April 3, 2011 as doi:10.1158/2159-8274.CD-11-0048.